EUCTR2006-003340-33-IT进行中（未招募）不适用
Preliminary evaluation of efficacy and tolerability of the association mesalazine 1g nifedipine 10mg in the treatment of tenesmus in patients suffering of distal ulcerative cholitis. Open study, phase II, two steps according to Simon - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- BRACCO
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Both sex aged 18 years or more. Diagnosis of ulcerative rectocholitis with tenesmus and 4 unproductive fecal discharge or more. Patients with stable concomitant therapies for almost 1 month Informed consent obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who start a concomitant therapy Pregnancy or lactation Alcohol or drugs abuse Known allergy to mesalazine or nifedipine Non collaborative patients Patients who join any other study during the last month Any othe severe pathologies which can interfere with the study.
研究者
相似试验
尚未招募
1 期
Combination therapy of iPS-NKT cell and DC/GalJPRN-jRCTa030220741Iinuma Tomohisa6
进行中（未招募）
1 期
Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19).The study population will consist of adults (18-80 years old) hospitalised for =48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test positive from nasopharyngeal swab. Patients with ARDS or patients requiring mechanical ventilation at screening or randomisation will be excludedMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002295-13-FRAssistance Publique - Hôpitaux Paris100
尚未招募
2 期
Preliminary evaluation of the efficacy and safety of Xuezhikang tablets (LY02404) in the treatment of hyperlipidemia: a multicenter, randomized, double-blind, double-simulation, parallel control of positive drugs, and dose-exploration phase II clinical trialITMCTR2000003402Peking University First Hospital
Unknown
3 期
Difluprednate 0.05% versus Prednisolone acetate 1% eye drops following phacoemulsification surgeryEye DiseasesPACTR202207762785564Suez Canal University Hospital800
已完成
不适用
Safety and efficacy of AKP-11 for atopic dermatitis.Skin - Dermatological conditionsAtopic DermatitisACTRN12616000294459Akaal Pharma PTY LTD21